HLA B Leader in Patients With Psoriatic Arthritis

NCT07718815 | Recruiting

• 1 other identifier: PI2024_843_0115
• Study Type: interventional
• Target: 658
• Locations: 1 country
• Sites: 1

Brief Summary

Psoriatic arthritis (PsA), a chronic immune-mediated heterogeneous inflammatory disease characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis and dactylitis), usually occurs in patients with psoriasis. The spondyloarthritides (SPs) (of which psoriasis is one) are a group of inflammatory diseases that share an association with the HLA-B27 MHC class I molecule. Given this association, these diseases are classically regarded as disorders of adaptive immunity. In bone marrow donation, HLA-B exon 1 dimorphism (HLAB leader) is associated with risk of graft- versus-host disease, relapse and overall survival after unrelated hematopoietic cell transplantation (UHCT), haploidentical UHCT and cord transplantation. In the literature, there are no studies suggesting the involvement of the HLA B leader gene in MS and RPs. The main aim of this study is to compare the presence of the HLA B leader gene between a group of patients with psoriatic arthritis and a healthy group without inflammatory disease.

Conditions

Psoriatic Arthritis; HLA b Leader; HLA B27

Keywords

Psoriatic arthritis; HLA b leader; HLA B27

Outcome Measures

Primary Outcomes (1)

• prevalence of HLA B leader in both groups

  prevalence of HLA B leader in patients with psoriatic rheumatism compared to the healthy group by autoimmune disease

  1 year

Secondary Outcomes (2)

• Prevalence of HLAB27 gene in both groups

  1 year

• prevalence of the HLAB27/ HLA b Leader gene in different forms of psoriatic rheumatism patient group

  1 year

Study Arms (2)

psoriatic rheumatism patient

EXPERIMENTAL

patients with psoriatic arthritis

Biological: blood test

healthy group

ACTIVE COMPARATOR

patients without inflammatory disease

Biological: blood test

Interventions

blood test BIOLOGICAL

Addition of an extra tube for blood tests (a single tube for genetic research), enabling phenotyping of the HLA B27 and HLA B leader genes.

healthy group; psoriatic rheumatism patient

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• For the "Patient" group:
• Patient over 18 years of age
• Patient affiliated to a social security scheme
• Patient with psoriatic arthritis according to the CASPAR 2006 classification, followed at the CHU Amiens-Picardie.
• For the "control" group:
• Individuals over 18 years of age
• Individual affiliated to a social security scheme
• Individual having agreed to participate in the study
• Individuals with no inflammatory or autoimmune diseases

You may not qualify if:

• Patient or control not understanding French
• Patient not included in the Amiens Picardie University Hospital's "Psoriatic Rheumatism" cohort, or control not included in the Amiens Picardie University Hospital's bone marrow donor cohort.
• Patient or control objecting to participation in the study

Sponsors & Collaborators

• Centre Hospitalier Universitaire, Amiens: lead

Study Sites (1)

CHU Amiens Picardie

Amiens, Picardie, 80054, France

RECRUITING

MeSH Terms

Conditions

Arthritis, Psoriatic

Interventions

Hematologic Tests

Condition Hierarchy (Ancestors)

Spondylarthropathies; Spondylarthritis; Spondylitis; Spinal Diseases; Bone Diseases; Musculoskeletal Diseases; Arthritis; Joint Diseases; Psoriasis; Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Investigative Techniques

Central Study Contacts

Vincent Goeb, Pr

CONTACT

33+3.22.08.83.71; Goeb.vincent@chu-amiens.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 16, 2026
• First Posted: July 22, 2026
• Study Start: May 6, 2025
• Primary Completion (Estimated): September 1, 2026
• Study Completion (Estimated): September 1, 2026
• Last Updated: July 22, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)